Karyopharm Therapeutics

Biopharmaceutical companies have not taken a summer break from layoffs and are not waiting until later this month, when many will begin reporting second quarter earnings, to reveal their latest rounds

Sage Therapeutics, Inc. has a lot to figure out in the coming weeks, now that the US Food and Drug Administration has approved Zurzuvae (zuranolone) for postpartum depression (PPD) but rejected the d

Drug development in hematology-oncology can sometimes happen at such a fast, paradigm-busting pace that the selection of treatments even 20 years ago can look like prehistory compared to what is avail

Chinese pharma companies are now taking some of their principal products to the smaller global markets of Southeast Asia, which a number are targeting in an expansion push. Hong Kong- and Shanghai-lis